Vendor Component Defects in a Regulated Device
You manage a medical device software project targeting FDA 510(k) clearance. A critical imaging component is outsourced to a vendor under a fixed-price contract with a 99.5% availability SLA and a 30-day cure period. During integration testing, the component failed 3.2% of test cases. The vendor claims the defects stem from your interface specification. Your risk register, last updated two months ago, lists vendor delay as low probability and high impact. The schedule has five days of float before a mandatory regulatory submission. A quality audit found missing traceability in two modules. The vendor invoice for the next milestone is due in 10 days, and the procurement manager wants to withhold payment. The project is 65% complete.
1. Reassess the vendor risk and recommend immediate risk responses, including contract levers.
Read the worked answer
The risk register is out of date. Vendor delay was rated low probability, but the 3.2% test failure rate and the five-day float make the risk both more probable and more imminent. The impact is high because a failed component can delay the regulatory submission and trigger rework.
Immediate responses:
- Convene a joint root-cause analysis with the vendor and your integration lead. Test the interface specification against actual failure cases to determine whether the defects are vendor-side, specification-side, or integration-side.
- Invoke the contract formally but proportionately. Issue a written notice describing the failures, reference the 99.5% SLA and 30-day cure period, and request a corrective action plan. Do not withhold the milestone invoice without checking the contract's payment terms, because an improper withholding could weaken your position.
- Develop a fallback plan. Identify whether an alternative component, workaround, or additional testing can protect the submission date. Even a low-probability fallback is warranted given the regulatory deadline.
- Update the risk register with new probability, impact, triggers, owner, and response, and report the change to the steering committee.
The key judgement is to act on evidence before the cure period expires, not to wait for the vendor to self-correct.
2. The vendor disputes responsibility. Outline a procurement negotiation and documentation approach.
Read the worked answer
I would treat this as a contract performance dispute, not a personal argument. First, assemble evidence: test logs, interface specification versions, acceptance criteria, correspondence, and the contract's defect and cure clauses. Establish a shared factual baseline before negotiating responsibility.
Next, request a formal dispute meeting with the vendor's account manager and technical lead. Present the evidence and ask the vendor to do the same. If the root cause is genuinely ambiguous, propose a joint verification test with agreed pass/fail criteria and a deadline. That is often faster than legal escalation and preserves the delivery relationship.
Documentation should include: a written notice of defect, meeting minutes, agreed actions with owners and dates, and all formal correspondence. If the vendor refuses to cooperate, escalate through the contract's dispute resolution clause and involve procurement and legal. The procurement manager should not withhold payment unilaterally unless the contract permits it; instead, document the dispute and follow the contractual remedy path. The goal is to resolve the technical issue quickly while preserving the organization's contractual rights.
3. Quality audit found missing traceability in two modules. Propose corrective actions and how to prevent recurrence.
Read the worked answer
Missing traceability in a regulated device project is a compliance defect, not just a documentation gap. Corrective action should first contain the problem: identify which requirements, design elements, and test cases are affected in the two modules, and reconstruct the trace links from existing records. Re-audit the modules after correction and record the evidence.
Root-cause analysis should ask why traceability was missed: unclear template, late requirement changes, insufficient review, or tooling gaps. Preventive actions should then address the cause. For example, add traceability completion as a gate criterion for design reviews and test readiness, update the quality management plan, and train the team on the specific tool and standard. Assign a quality reviewer to sample traceability at each module completion rather than waiting for a final audit.
The project manager should also check whether the same weakness exists in other modules. If two modules failed, the probability of similar gaps elsewhere is high. Report the corrective action plan to the quality function and track it in the issue log until verification is complete.